Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Dr. Natasha Leighl's Highlights in Lung Cancer from 2012: Developments for EGFR Mutation-Positive NSCLC
Author
Howard (Jack) West, MD

EGFR Mutn Pos NSCLCHere is the first of the awaited podcasts from Dr. Natasha Leighl's presentation on "Highlights in Lung Cancer from 2012".  Dr. Leighl is a longtime friend who is a lung cancer expert at Princess Margaret Hospital in Toronto, Ontario, Canada, and she covered a wide range of topics that represented promising developments in the field for the past year, some of which likely to lead to new treatment options for patients in the clinic over the next few years. 

The first part of her talk covered new information on potential treatment options for patients with advanced NSCLC that has an activating EGFR mutation.  Here's the video and audio versions of the podcast, along with the figures for it.  (We're going to forgo the transcript, since it's a time-consuming process, and I don't think there's a major audience for it -- tell us if there's a clear need for the transcripts for these programs that we're not seeing).

[powerpress]

Dr. Leighl Highlights in LC 2012: Pt 1 EGFR Mutn Pos Audio Podcast

Dr. Leighl Highlights in LC 2012 Pt 1 EGFR Mutn Pos Figures

We've got more parts of her presentation waiting in the wings, so check back for more highlights in lung cancer soon.

 

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora